Baseline characteristics and patient disposition

CV risk factors and ARV therapy at screening

Outcome at W 48, ITT

- Confirmed virological failure (HIV RNA > 50 c/mL): DTG, N = 4 vs PI/r, N = 1 ; genotype successful in 2/4 and 0/1 patients: no emergence of resistance mutations
Treatment success at W48 (ITT, per- protocol and sub -groups)

Fasting plasma lipids ( mmol /L): mean percentage change at W48

- No changes in the utilization of lipid lowering agents (around 30% in each arm, both at baseline and W48)
Adverse events, %

* Acute HCV infection (N = 1), mood and/or sleep disorders (N = 6)
** Acute HCV infection (N = 1), dyspepsia (N = 1), worsening of renal function (N = 1)
Median change in eGFR (CKD-EPI) at W48 (p < 0.001)
- ‒ DTG: ~ - 8 ml/min
- PI/r: 0 ml/min